BeOne Medicines (ONC) Competitors

$294.90 -9.72 (-3.19%)

As of 03:16 PM Eastern

ONC vs. SNY, GSK, TAK, ARGX, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? MarketBeat compares BeOne Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeOne Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does BeOne Medicines compare to Sanofi?

BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74B	5.64	$286.93M	$4.47	65.97
Sanofi	$47.35B	2.20	$8.84B	$3.58	11.95

BeOne Medicines has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

BeOne Medicines currently has a consensus price target of $389.15, suggesting a potential upside of 31.96%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 19.17%. Given BeOne Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Sanofi	16.95%	13.39%	7.58%

In the previous week, BeOne Medicines had 6 more articles in the media than Sanofi. MarketBeat recorded 11 mentions for BeOne Medicines and 5 mentions for Sanofi. BeOne Medicines' average media sentiment score of 0.72 beat Sanofi's score of 0.57 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BeOne Medicines beats Sanofi on 11 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74B	5.64	$286.93M	$4.47	65.97
GSK	$43.07B	2.34	$7.54B	$3.85	12.87

BeOne Medicines has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, GSK has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

BeOne Medicines currently has a consensus price target of $389.15, suggesting a potential upside of 31.96%. GSK has a consensus price target of $53.00, suggesting a potential upside of 6.93%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
GSK	17.82%	44.28%	11.49%

In the previous week, BeOne Medicines had 3 more articles in the media than GSK. MarketBeat recorded 11 mentions for BeOne Medicines and 8 mentions for GSK. BeOne Medicines' average media sentiment score of 0.72 beat GSK's score of 0.12 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats GSK on 11 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BeOne Medicines has a consensus price target of $389.15, suggesting a potential upside of 31.96%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 11 articles in the media. BeOne Medicines' average media sentiment score of 0.72 beat Takeda Pharmaceutical's score of -0.01 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Takeda Pharmaceutical's net margin of 4.31%. BeOne Medicines' return on equity of 12.06% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.23%	5.54%
BeOne Medicines	8.94%	12.06%	6.69%

Takeda Pharmaceutical has higher revenue and earnings than BeOne Medicines. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.87	$712.33M	$0.39	42.65
BeOne Medicines	$5.74B	5.64	$286.93M	$4.47	65.97

Takeda Pharmaceutical has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

BeOne Medicines beats Takeda Pharmaceutical on 14 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to argenex?

argenex (NASDAQ:ARGX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

60.3% of argenex shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

argenex presently has a consensus price target of $1,017.78, suggesting a potential upside of 26.17%. BeOne Medicines has a consensus price target of $389.15, suggesting a potential upside of 31.96%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, argenex had 6 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for argenex and 11 mentions for BeOne Medicines. argenex's average media sentiment score of 0.75 beat BeOne Medicines' score of 0.72 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 33.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
BeOne Medicines	8.94%	12.06%	6.69%

argenex has higher earnings, but lower revenue than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.81	$1.29B	$22.46	35.91
BeOne Medicines	$5.74B	5.64	$286.93M	$4.47	65.97

argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

argenex beats BeOne Medicines on 12 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

In the previous week, BeOne Medicines had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 11 mentions for BeOne Medicines and 10 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.84 beat BeOne Medicines' score of 0.72 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BeOne Medicines' net margin of 8.94%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BeOne Medicines	8.94%	12.06%	6.69%

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	25.91
BeOne Medicines	$5.74B	5.64	$286.93M	$4.47	65.97

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, suggesting a potential upside of 21.23%. BeOne Medicines has a consensus price target of $389.15, suggesting a potential upside of 31.96%. Given BeOne Medicines' higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Teva Pharmaceutical Industries beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.39B	$2.99B	$6.23B	$12.32B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	66.04	18.04	20.39	25.37
Price / Sales	5.64	259.11	541.93	73.28
Price / Cash	80.99	57.78	43.26	56.33
Price / Book	6.80	4.31	9.82	6.93
Net Income	$286.93M	$72.19M	$3.56B	$333.88M
7 Day Performance	-5.52%	-2.34%	0.60%	0.33%
1 Month Performance	-7.83%	-2.62%	-0.70%	2.11%
1 Year Performance	30.62%	41.07%	36.51%	33.31%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.352 of 5 stars	$294.90 -3.2%	$389.15 +32.0%	+38.5%	$32.39B	$5.74B	66.04	12,000	Analyst Forecast
SNY Sanofi	4.3612 of 5 stars	$43.31 +0.3%	$51.00 +17.8%	-12.9%	$105.63B	$49.35B	12.10	74,846	Analyst Upgrade
GSK GSK	3.4172 of 5 stars	$50.38 -0.2%	$53.00 +5.2%	+40.4%	$102.29B	$43.07B	13.09	66,841	Dividend Cut
TAK Takeda Pharmaceutical	2.1482 of 5 stars	$16.49 -0.9%	N/A	+21.5%	$52.38B	$30.09B	68.69	47,455	News Coverage Earnings Report
ARGX argenex	4.7236 of 5 stars	$782.17 -0.7%	$1,017.78 +30.1%	+54.5%	$48.64B	$4.25B	34.83	1,863	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. SNY, GSK, TAK, ARGX, and TEVA

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to argenex?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. SNY, GSK, TAK, ARGX, and TEVA

How does BeOne Medicines compare to Sanofi?

Which has preferable valuation & earnings, ONC or SNY?

Which has more risk and volatility, ONC or SNY?

Do analysts rate ONC or SNY?

Is ONC or SNY more profitable?

Does the media prefer ONC or SNY?

Do institutionals & insiders hold more shares of ONC or SNY?

Summary

How does BeOne Medicines compare to GSK?

Which has better valuation and earnings, ONC or GSK?

Which has more volatility & risk, ONC or GSK?

Do analysts recommend ONC or GSK?

Is ONC or GSK more profitable?

Does the media favor ONC or GSK?

Do insiders and institutionals hold more shares of ONC or GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Do institutionals and insiders hold more shares of TAK or ONC?

Do analysts rate TAK or ONC?

Does the media refer more to TAK or ONC?

Is TAK or ONC more profitable?

Which has better earnings & valuation, TAK or ONC?

Which has more volatility & risk, TAK or ONC?

Summary

How does BeOne Medicines compare to argenex?

Do institutionals and insiders hold more shares of ARGX or ONC?

Do analysts rate ARGX or ONC?

Does the media refer more to ARGX or ONC?

Is ARGX or ONC more profitable?

Which has better earnings & valuation, ARGX or ONC?

Which has more volatility & risk, ARGX or ONC?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Do insiders & institutionals hold more shares of TEVA or ONC?

Which has more risk & volatility, TEVA or ONC?

Does the media refer more to TEVA or ONC?

Is TEVA or ONC more profitable?

Which has preferable earnings and valuation, TEVA or ONC?

Do analysts rate TEVA or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools